Antiviral UCPH spinout powers up after September's big capital injection
The biotech firm Synklino, which is developing an antiviral treatment and whose owner group was joined by two funds last month, has hired two experienced biotech profiles to raise around EUR 30m in the spring and bring the firm's drug through phase I.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
The Copenhagen-based firm Synklino, which is developing an antiviral drug, received a capital injection worth DKK 13m (USD 2.0m) in September from the newly established life science fund Eir Ventures and the Danish Growth fund – and the company has wasted no time putting this money to use.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
